Benoist GE, Hendriks RJ, Mulders PFA, Gerritsen WR, Somford DM, Schalken JA, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55:1369–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

Article  CAS  PubMed  Google Scholar 

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

Article  PubMed  PubMed Central  Google Scholar 

Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023;41:4267–78.

Article  CAS  PubMed  Google Scholar 

Danielak D, Krejčí T, Beránek J. Increasing the efficacy of abiraterone—from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. 2022;176: 106254.

Article  CAS  PubMed  Google Scholar 

Hu Y, Wu J, Cheng B, You R, Yin X, Chen G, et al. Effect of food and polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers. Br J Clin Pharmacol. 2024;90:247–63.

Article  CAS  PubMed  Google Scholar 

Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014;53:1149–60.

Article  CAS  PubMed  Google Scholar 

Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer Oxf Engl. 1990;2017(72):54–61.

Google Scholar 

van Nuland M, Groenland SL, Bergman AM, Steeghs N, Rosing H, Venekamp N, et al. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:244–51.

Article  PubMed  Google Scholar 

Groenland SL, van Nuland M, Bergman AM, de Feijter JM, Dezentje VO, Rosing H, et al. Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. Eur J Cancer Oxf Engl. 1990;2020(130):32–8.

Google Scholar 

Blanchet B, Carton E, Alyamani M, Golmard L, Huillard O, Thomas-Scheomann A, et al. A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. Pharmacol Res. 2018;136:56–61.

Article  CAS  PubMed  Google Scholar 

Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.

Article  CAS  PubMed  Google Scholar 

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018;36:1389–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, et al. High-Dose abiraterone acetate in men with castration resistant prostate cancer. Clin Genitourin Cancer. 2017;15:733-741.e1.

Article  PubMed  Google Scholar 

European Medical Agency. Summary of Products Characteristics : Abiraterone. https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga.

Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S. Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic. Presse Medicale Paris Fr. 1983;2001(30):1044–8.

Google Scholar 

Belleville T, Noé G, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, et al. A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;989:86–90.

Article  CAS  PubMed  Google Scholar 

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.

Article  PubMed  PubMed Central  Google Scholar 

Menssouri N, Poiraudeau L, Helissey C, Bigot L, Sabio J, Ibrahim T, et al. Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen receptor pathway inhibitors. Clin Cancer Res. 2023;29:4504–17.

Article  CAS  PubMed  Google Scholar 

Takahashi Y, Narita S, Shiota M, Miura M, Kagaya H, Kashima S, et al. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate. Eur J Clin Pharmacol. 2023;79:89–98.

Article  CAS  PubMed  Google Scholar 

Janssen JM, Dorlo TPC, Beijnen JH, Huitema ADR. Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs. Ther Drug Monit. 2020;42:532–9.

Article  PubMed  Google Scholar 

Lam WY, Fresco P. Medication adherence measures: an overview. BioMed Res Int. 2015;2015: 217047.

Article  PubMed  PubMed Central  Google Scholar 

Nguyen T-M-U, La Caze A, Cottrell N. What are validated self-report adherence scales really measuring? A systematic review. Br J Clin Pharmacol. 2014;77:427–45.

Article  PubMed  PubMed Central  Google Scholar 

Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, et al. Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in new-onset metastatic castration-resistant prostate cancer (mCRPC). Mol Cancer Ther. 2019;18:726–9.

Article  CAS  PubMed  Google Scholar 

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, et al. Association of tissue abiraterone levels and SLCO genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer. Clin Cancer Res. 2017;23:4592–601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrero J-M, Mahammedi H, Gravis G, Roubaud G, Beuzeboc P, Largillier R, et al. Abigene, a prospective, multicentric study of abiraterone acetate pharmacogenetics in metastatic castration-resistant prostate cancer. Pharmaceutics. 2023;15:651.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Medwid S, Price HR, Taylor DP, Mailloux J, Schwarz UI, Kim RB, et al. Organic anion transporting polypeptide 2B1 (OATP2B1) genetic variants: in vitro functional characterization and association with circulating concentrations of endogenous substrates. Front Pharmacol. 2021;12: 713567.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29:2565–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Harshman LC, Xie W, Nakabayashi M, Qu F, Pomerantz MM, et al. Association of SLCO2B1 genotypes with time to progression and overall survival in patients receiving androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2016;34:352–9.

Article  PubMed  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

Article  CAS  PubMed  Google Scholar